| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 18 Jul 2024 | 14 Jul 2024 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/07/2024 inter alia to consider and approve A meeting of the Board of Directors of the Company will be held on Thursday July 18 2024 to consider inter alia a proposal for buyback of the fully paid-up equity shares of the Company and the matters necessary and incidental thereto in accordance with the applicable provisions under the Companies Act 2013 the Securities and Exchange Board of India (Buy-back of Securities) Regulations 2018 and other applicable laws Intimation of outcome of Board meeting where the Board has approved buyback of equity shares of the Company. (As per BSE Announcement Dated on 18/07/2024) | ||
| Board Meeting | 25 May 2024 | 16 May 2024 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve Consideration and approval of inter alia audited financial results for the 4th quarter and the financial year ended on March 31 2024. Submission of outcome of Board meeting held on 25th May 2024 Submission of Audited Financial Results for the fourth quarter and financial year ended on March 31, 2024 Intimation of reappointment / continuation of directors subject to approval of shareholders (As Per BSE Announcement Dated on 25/05/2024) | ||
| Board Meeting | 27 Mar 2024 | 27 Mar 2024 |
| Intimation of changes in Board of Directors of the Company | ||
| Board Meeting | 10 Feb 2024 | 1 Feb 2024 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Intimation of Board meeting on Saturday 10th February 2024 for consideration of unaudited standalone and consolidated financial results for the 3rd quarter and 9 month period ended on 31st December 2023. The Board of Directors in its meeting convened to be held on 10th February 2024 will also consider the payment of second interim dividend, if any, for the financial year 2023-24. (As Per BSE Announcement dated on 07.02.2024) Board of Directors in their meeting held today, February 10, 2024, approved the payment of Second Dividend of 150% i.e. Rs.1.50 per shares of Re.1 each. Board of Directors in their meeting held today, February 10, 2024, appointed Dr. Deepali Pant Joshi as an Independent Director (subject to approval of shareholders) and accepted the resignation of Dr. Avnit Bimal Singh as an Independent Director. (As Per BSE Announcement Dated on 10.02.2024) | ||
| Board Meeting | 9 Nov 2023 | 27 Oct 2023 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday November 9 2023 to consider and approve inter alia the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2023 and 2. payment of Interim Dividend if any for the financial year 2023-24. Intimation of November 20, 2023 as Record Date for payment of Interim Dividend for FY 2023-24, if declared. (As Per BSE Announcement Dated on 02.11.2023) The Board of Directors of the Company at its meeting held today, November 9, 2023, has inter alia, transacted the following items of business: 1. Approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. 2. Approved first interim dividend of 300% i.e., Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed November 20, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2023-24 and the said interim dividend will be paid on or before December 4, 2023. 3. Based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members through postal ballot, approved the appointment of Dr.Satakarni Makkapati (DIN. 09377266) as Nonexecutive and Non-independent Director of the Company with effect from November 9, 2023. 4. Approved purchase of entire equity shares of Theranym Biologics Private Limited, a step-down wholly owned subsidiary of the Company, from Curateq Biologics Private Limited, also a wholly owned subsidiary of the Company and make Theranym Biologics Private Limited a direct subsidiary of the Company. The Board meeting commenced at 3.30 p.m. and concluded at 7.00 p.m. Outcome of Board meeting held on 9th November 2023 Board has approved the acquisition entire equity share capital of Theranym Biologics Private Limited, a 100% stepdown subsidiary, to make it a direct subsidiary. Board of Directors appointed Dr. Satakarni Makkapati as Non-executive and Non-independent Director of the Company. (As Per BSE Announcement Dated on 09.11.2023) | ||
| Board Meeting | 12 Aug 2023 | 3 Aug 2023 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that a Meeting of the Board of Directors of the Company will be held on Saturday August 12 2023 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30 2023. Further to our letter dated June 28 2023 informing the closure of Trading Window of the Company from July 1 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30 2023 we inform you that the Trading Window will remain closed up to August 14 2023 and shall be re-opened on August 15 2023. The Board of Directors of the Company at its meeting held today, August 12, 2023, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2023, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company. The Board meeting commenced at 3.30 p.m. and concluded at 5.40 p.m. Board has approved the following in its meeting held today, 12 August 2023: Has reinitiated to explore restructuring of Eugia Pharma Specialities Limited and Has accepted the resignation of Dr.M.Sivakumaran as Whole-time Director and Director of the Company w.e.f. August 24, 2023 The Board of Directors in its meeting held today, August 12, 2023, has accepted the resignation of Dr. M. Sivakumaran as Whole-time Director and Director of the Company on close of business hours of August 24, 2023. (As per BSE Announcement Dated on 12/08/2023) | ||
The record date for the share buyback has been set as July 30, 2024. Promoters will also participate in the share buyback.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
